Ironwood Pharmaceuticals, Inc. (IRWD) EPS Estimated At $-0.19

September 30, 2018 - By Pearl Odom

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) LogoInvestors sentiment increased to 1.03 in Q2 2018. Its up 0.33, from 0.7 in 2018Q1. It increased, as 19 investors sold Ironwood Pharmaceuticals, Inc. shares while 43 reduced holdings. 22 funds opened positions while 42 raised stakes. 146.28 million shares or 2.74% less from 150.40 million shares in 2018Q1 were reported.
Shell Asset Mgmt owns 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 13,094 shares. Farmers Retail Bank holds 0.01% or 450 shares. 35,478 were reported by Jefferies Grp Incorporated Lc. Moreover, Vanguard Grp Incorporated has 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Balyasny Asset Management Limited Com holds 17,412 shares or 0% of its portfolio. State Of Wisconsin Invest Board holds 435,030 shares or 0.02% of its portfolio. Deutsche Fincl Bank Ag has invested 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Penn Capital Mngmt Communication invested in 1.29% or 900,856 shares. Sg Americas Limited reported 30,811 shares. Atika Capital Mngmt Limited Liability Corp holds 0.6% or 164,000 shares. 7,245 were reported by Bnp Paribas Arbitrage. Sarissa Capital Mngmt L P stated it has 3.37 million shares. Ecor1 Capital Limited Liability Corporation stated it has 11.38% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Employees Retirement Of Ohio holds 120,370 shares. Teachers Retirement System Of The State Of Kentucky holds 0.14% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 616,747 shares.

Since June 5, 2018, it had 0 insider purchases, and 9 sales for $4.91 million activity. McHugh Julie had sold 1,500 shares worth $28,650. $2.40 million worth of stock was sold by Currie Mark G on Wednesday, August 22. $38,200 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares were sold by OLANOFF LAWRENCE S. On Friday, August 17 the insider Consylman Gina sold $3,423. $583,632 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares were sold by Gilbert Halley E.

Analysts expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report $-0.19 EPS on November, 1.They anticipate $0.01 EPS change or 5.56 % from last quarter’s $-0.18 EPS. After having $-0.28 EPS previously, Ironwood Pharmaceuticals, Inc.’s analysts see -32.14 % EPS growth. The stock increased 0.87% or $0.16 during the last trading session, reaching $18.46. About 871,830 shares traded or 1.42% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 14.01% since September 30, 2017 and is uptrending. It has underperformed by 1.61% the S&P500.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 7 analysts covering Ironwood Pharma (NASDAQ:IRWD), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Ironwood Pharma had 9 analyst reports since April 19, 2018 according to SRatingsIntel. On Wednesday, May 9 the stock rating was downgraded by Morgan Stanley to “Underweight”. Mizuho upgraded the stock to “Buy” rating in Wednesday, May 2 report. As per Thursday, May 31, the company rating was maintained by Wells Fargo. The firm has “Buy” rating by Mizuho given on Thursday, May 31. Berenberg initiated it with “Buy” rating and $2500 target in Thursday, April 19 report. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Outperform” rating given on Thursday, August 9 by Wells Fargo. The firm earned “Market Perform” rating on Wednesday, July 18 by Cowen & Co.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.83 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Another recent and important Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news was published by Streetinsider.com which published an article titled: “Ironwood Pharma (IRWD) Announces FDA Fast Track Designation for Praliciguat for Heart Failure” on September 13, 2018.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: